시간 외 거래: 1.34 0.01 +0.75%

Clearmind Medicine Inc (CMND)

Clearmind Medicine Inc 주식(CMND)의 최신 뉴스

Clearmind Medicine Inc (CMND)

Clearmind Medicine Inc 주식(CMND)의 최신 뉴스

Contrasting Clearmind Medicine (NASDAQ:CMND) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World

Clearmind Medicine files patent for PTSD treatment compounds - Investing.com

Clearmind Medicine files patent for PTSD treatment compounds - Investing.com India

SciSparc shares up on patents filed for psychedelic compounds with Clearmind - MSN

SciSparc and Clearmind Innovate Mental Health Treatment - TipRanks

Clearmind Medicine files patent for novel MDMA therapy - Investing.com

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Yahoo Finance UK

SciSparc-Clearmind Medicine Collaboration Leads to - GlobeNewswire

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent ... - The Bakersfield Californian

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - StockTitan

A History of Outperforming Analyst Forecasts and Beating the Odds: Clearmind Medicine Inc (CMND) - SETE News

Financial Metrics Check: Clearmind Medicine Inc (CMND)’s Ratios for Trailing Twelve Months - The Dwinnex

Clearmind and SciSparc file patent for ketamine-based therapy - Investing.com

SciSparc and Clearmind Innovate in Mental Health Therapy - TipRanks

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment - Morningstar

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination - StockTitan

Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes - Benzinga

CMND’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Clearmind receives patent for drug to treat binge behavior - Green Market Report

Clearmind Medicine Inc (CMND) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Clearmind Medicine secures new US patent for binge behavior regulator - Investing.com India

Clearmind Medicine secures new US patent for binge behavior regulator - Investing.com

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - Yahoo Finance

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - Morningstar

Clearmind Medicine Inc (CMND) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Is CMND’s price to cash per share ratio a concern for investors? - US Post News

Financial Metrics Unveiled: Clearmind Medicine Inc (CMND)’s Key Ratios in the Spotlight - The Dwinnex

Thinking about buying stock in Brainstorm Cell Therapeutics, Cle - GuruFocus.com

Clearmind, Yissum Apply for International Patent for Psychedelics - MarketWatch

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders - StockTitan

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders - Morningstar

Clearmind Medicine (NASDAQ:CMND) Stock Price Down 0.8% - Defense World

Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug - EIN News

SciSparc and Clearmind report progress in obesity treatment - Investing.com

Move over Ozempic, psychedelics might help people lose weight - Green Market Report

SciSparc’s Collaboration with Clearmind Medicine Continues - GlobeNewswire

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug - StockTitan

Clearmind gains on exclusive global rights to psychedelic compounds for PTSD treatment - MSN

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 - EIN News

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research - Morningstar

Clearmind Medicine (NASDAQ:CMND) Stock Quotes, Forecast and News Summary - Benzinga

Clearmind partners for global roll-out of alcohol substitute By Investing.com - Investing.com South Africa

Clearmind partners for global roll-out of alcohol substitute - Investing.com India

Clearmind partners for global roll-out of alcohol substitute - Investing.com

Clearmind Medicine to source manufacturers and distributors for its alcohol substitute beverage product - Seeking Alpha

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product - StockTitan

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product - Afternoon Headlines

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product - Morningstar

Clearmind Medicine (NASDAQ:CMND) Stock Price Down 2.8% - Defense World

Market Watch: Clearmind Medicine Inc (CMND)’s Noteworthy Drop, Closing at 1.83 - The Dwinnex

SciSparc and Clearmind submit new patent application By Investing.com - Investing.com Canada

Nasdaq Edges Lower; Morgan Stanley Earnings Top Views - Benzinga

FDA clears Clearmind's drug trial for alcohol disorder - Investing.com

FDA clears Clearmind's drug trial for alcohol disorder - Investing.com India

Clearmind gets FDA approval for alcohol addiction treatment study - Green Market Report

Crude Oil Down 1%; Bank of America Posts Upbeat Earnings - Benzinga

SciSparc and Clearmind submit new patent application By Investing.com - Investing.com Nigeria

SciSparc and Clearmind submit new patent application - Investing.com India

CMND’s 2023 Market Dance: Down -21.00% – Time to Invest? - The InvestChronicle

Why Is SciSparc (SPRC) Stock Up 25% Today? - InvestorPlace

SciSparc and Clearmind submit new patent application - Investing.com

Dow Jumps 400 Points; US Retail Sales Flat For June - Benzinga

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism - Marketscreener.com

The growth track for Clearmind Medicine Inc (CMND) has changed recently - SETE News

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss - GlobeNewswire

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss - Morningstar

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss - Afternoon Headlines

Investors love Legend Biotech Corporation (NASDAQ: LEGN) stock and here’s why - BP Journal

Qualigen Therapeutics (QLGN) Secures New Financing to Propel Growth - BP Journal

CMND과 유사한 종목